{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=12",
    "query": {
      "condition": "Ovarian Tumors",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 2458,
    "total_pages": 246,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:48:49.070Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01248949",
      "title": "A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Advanced Recurrent Ovarian Tumors"
      ],
      "interventions": [
        {
          "name": "MEDI3617",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 162,
      "start_date": "2010-10",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01248949"
    },
    {
      "nct_id": "NCT06856499",
      "title": "Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Endometrioid Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Cirtuvivint",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-12-08",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06856499"
    },
    {
      "nct_id": "NCT01696032",
      "title": "SGI-110 in Combination With Carboplatin in Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "SGI-110",
          "type": "DRUG"
        },
        {
          "name": "Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2012-09",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Augusta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696032"
    },
    {
      "nct_id": "NCT01428193",
      "title": "Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Hyperandrogenism"
      ],
      "interventions": [
        {
          "name": "Flutamide",
          "type": "DRUG"
        },
        {
          "name": "Progesterone",
          "type": "DRUG"
        },
        {
          "name": "estrace",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 17 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2006-09",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-04",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01428193"
    },
    {
      "nct_id": "NCT00635193",
      "title": "Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer, Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "M200 (Volociximab)",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 138,
      "start_date": "2007-07",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 14,
      "location_summary": "Anaheim, California • Redondo Beach, California • Sunrise, Florida + 11 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635193"
    },
    {
      "nct_id": "NCT02764333",
      "title": "TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TPIV200",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2016-05-06",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02764333"
    },
    {
      "nct_id": "NCT03219268",
      "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Hematologic Neoplasms",
        "Ovarian Cancer",
        "HER2-positive Advanced Solid Tumors",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cholangiocarcinoma",
        "Cervical Cancer",
        "TNBC - Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tebotelimab 1 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 3 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 10 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 30 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 120 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 300 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 600 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 800 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tebotelimab 1200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "margetuximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2017-08-18",
      "completion_date": "2023-02-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 15,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219268"
    },
    {
      "nct_id": "NCT01121640",
      "title": "A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "CA125 assay on Abbott Architect i1000SR platform",
          "type": "PROCEDURE"
        },
        {
          "name": "HE4 assay on Architect i1000SR platform",
          "type": "PROCEDURE"
        },
        {
          "name": "Transvaginal Ultrasound",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 80 Years · Female only"
      },
      "enrollment_count": 854,
      "start_date": "2009-11",
      "completion_date": "2015-05-07",
      "has_results": false,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01121640"
    },
    {
      "nct_id": "NCT05903404",
      "title": "PCOS Indirect and Intangible Economic Burden",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "PCOS Challenge: The National Polycystic Ovary Syndrome Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2022-06-22",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05903404"
    },
    {
      "nct_id": "NCT00993655",
      "title": "Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Metastatic Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Canadian Cancer Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 275,
      "start_date": "2010-03-03",
      "completion_date": "2016-07-11",
      "has_results": true,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-10-14T11:48:49.070Z",
      "location_count": 6,
      "location_summary": "Springfield, Missouri • Oklahoma City, Oklahoma • Providence, Rhode Island + 2 more",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00993655"
    }
  ]
}